Unique ID issued by UMIN | UMIN000025397 |
---|---|
Receipt number | R000029236 |
Scientific Title | Effect of Salacia oblonga extract on blood pressure in high-normal blood pressure or grade I hypertension subjects: a dose-comparison trial |
Date of disclosure of the study information | 2016/12/27 |
Last modified on | 2017/08/09 14:47:17 |
Effect of Salacia oblonga extract on blood pressure in high-normal blood pressure or grade I hypertension subjects: a dose-comparison trial
Effect of Salacia oblonga extract on blood pressure in high-normal blood pressure or grade I hypertension subjects: a dose-comparison trial
Effect of Salacia oblonga extract on blood pressure in high-normal blood pressure or grade I hypertension subjects: a dose-comparison trial
Effect of Salacia oblonga extract on blood pressure in high-normal blood pressure or grade I hypertension subjects: a dose-comparison trial
Japan |
Healthy volunteers
Hypertension
Cardiology | Adult |
Others
NO
To evaluate blood pressure-lowering effect of Salacia oblonga extract comparing two doses in high-normal blood pressure or grade I hypertension subjects.
Efficacy
Exploratory
Pragmatic
Not applicable
3-week change in home blood pressure
3-week change in ankle-brachial index (ABI) and office blood pressure
Interventional
Parallel
Randomized
Individual
Double blind -all involved are blinded
Dose comparison
YES
NO
YES
Central registration
2
Prevention
Food |
Subjects receive 6 tablets/day (2 tablets/time) containing a total of 180 mg of Salacia oblonga extract for 3 weeks.
Subjects receive 6 tablets/day (2 tablets/time) containing a total of 540 mg of Salacia oblonga extract for 3 weeks.
20 | years-old | <= |
70 | years-old | >= |
Male and Female
1) Diagnosed as high-normal blood pressure or grade I hypertension through health checks twice or more in three years
2) With habit of eating 3 meals a day
1) Taking antihypertensive
2) Taking medicines for chronic disease other than antihypertensive
3) Taking functional food that may affect the trial
4) Participation in any clinical trial within 90 days of the commencement of the trial
5) In pregnancy or nursing a child
6) Judged as ineligible by clinical investigators
40
1st name | |
Middle name | |
Last name | Fumiko Higashikawa |
Hiroshima University, Institute of Biomedical & Health Sciences
Project Research Center for Clinical Trial and Preventive Medicine
Kasumi 1-2-3, Minami-ku, Hiroshima 734-8551, JAPAN
082-257-1533
fumiko@hiroshima-u.ac.jp
1st name | |
Middle name | |
Last name | Fumiko Higashikawa |
Hiroshima University, Institute of Biomedical & Health Sciences
Project Research Center for Clinical Trial and Preventive Medicine
Kasumi 1-2-3, Minami-ku, Hiroshima 734-8551, JAPAN
082-257-1533
fumiko@hiroshima-u.ac.jp
Hiroshima University
TAKAMA Co., Ltd.
Profit organization
NO
広島大学病院(広島県)
2016 | Year | 12 | Month | 27 | Day |
Unpublished
Completed
2016 | Year | 12 | Month | 22 | Day |
2017 | Year | 02 | Month | 10 | Day |
2016 | Year | 12 | Month | 26 | Day |
2017 | Year | 08 | Month | 09 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000029236